Skip to main content

Table 3 Factors related to the uptake of colorectal cancer screeninga for lung cancer survivors

From: Factors related with colorectal and stomach cancer screening practice among disease-free lung cancer survivors in Korea

Variables All patients (N = 829) Male patients (N = 641) Female patients (N = 188)
% Age-adjusted OR (95% CI) Multivariate ORb (95% CI) % Age-adjusted OR (95% CI) Multivariate ORb (95% CI) % Age-adjusted OR (95% CI) Multivariate ORb (95% CI)
Receiving physician advice to screen for SPC
 No 23.3 1.0 1.0 22.9 1.0 1.0 25.0 1.0 1.0
 Yes 29.0 1.52 (1.09–2.12) 1.37 (0.99–1.91) 29.2 1.38 (0.96–1.99) 1.46 (1.00–2.12) 28.2 1.30 (0.68–2.48) 1.14 (0.53–2.48)
Perceived risk of SPC in lung cancer survivors
 Lower than general population (GP) 21.6 1.0 1.0 22.0 1.0 1.0 20.0 1.0 1.0
 Same or higher than GP 25.9 1.07 (0.60–1.91) 1.14 (0.65–2.03) 25.7 1.16 (0.62–2.16) 1.13 (0.59–2.15) 26.6 1.08 (0.32–3.62) 1.37 (0.33–5.63)
Monthly household income, $(US)
  < 1000 24.2 1.0 1.0 24.6 1.0 1.0 22.5 1.0 1.0
 1000–2999 21.6 1.96 (0.73–1.67) 0.73 (0.48–1.12) 22.5 0.85 (0.55–1.32) 0.68 (0.43–1.10) 17.9 0.88 (0.44–4.48) 1.51 (0.47–4.88)
  ≥ 3000 34.5 1.45 (0.91–2.30) 1.22 (0.74–2.02) 32.2 1.47 (0.89–2.41) 1.02 (0.58–1.82) 40.7 2.98 (1.18–7.53) 5.09 (1.28–20.14)
Education
  ≤ 6 years 20.8 1.0 1.0 17.8 1.0 1.0 28.6 1.0 1.0
 7–11 years 25.3 1.33 (0.86–2.05) 1.34 (0.87–2.09) 27.4 1.73 (1.05–2.84) 1.91 (1.13–3.23) 17.7 0.56 (0.25–1.27) 0.34 (0.12–0.94)
  ≥ 12 years 33.2 1.78 (1.11–2.88) 1.76 (1.05–2.96) 30.3 2.14 (1.25–3.68) 1.87 (1.02–3.41) 48.3 2.75 (1.12–6.78) 1.35 (0.40–4.48)
  1. OR odds ratio, CI confidence interval, SPC second primary cancer
  2. aSubjects who received FOBT within 1 year, a double-contrast barium enema within 5 years, sigmoidoscopy within 5 years, or colonoscopy within 10 years were defined as receiving appropriate colorectal cancer screening
  3. bAdjusted for age, stage, marital status, education, family income status, smoking status, alcohol consumption, receiving recommendation for other cancer screening, and perception of secondary cancer risks